Hetzel D J, Hansky P J, Shearman D J, Korman M G, Hecker R, Taggart G J, Jackson R, Gabb B W
Gastroenterology. 1978 Feb;74(2 Pt 2):389-92.
Eighty-five patients with endospcopically confirmed duodenal or pyloric canal ulcers entered a double blind trial with 1200 mg of cimetidine per day or placebo for 6 weeks. Eighty-four per cent of patients treated with cimetidine and 38 percent of those receiving placebo healed their ulcers (P less than 0.001). Measurement of basal acid output and maximal acid output before and after treatment showed no significant change but patients who failed to heal their ulcers had a higher basal acid output and maximal acid output than those who healed. Patients who smoked or drank alcohol had the same healing rate as abstainers. Sity-seven patients with duodenal ulceration healed by a 6-week course of cimetidine were randomly allocated to 400 mg of cimetidine twice daily or placebo in the maintenance trial. Actuarial analysis of the number of relapses in each group demonstrates that cimetidine is highly effective in preventing relapse.
85例经内镜确诊为十二指肠溃疡或幽门管溃疡的患者进入一项双盲试验,接受每日1200毫克西咪替丁或安慰剂治疗,为期6周。接受西咪替丁治疗的患者中有84%的溃疡愈合,而接受安慰剂治疗的患者中这一比例为38%(P小于0.001)。治疗前后基础胃酸分泌量和最大胃酸分泌量的测量结果显示无显著变化,但溃疡未愈合的患者比愈合的患者基础胃酸分泌量和最大胃酸分泌量更高。吸烟或饮酒的患者与戒酒者的愈合率相同。在维持试验中,77例经6周西咪替丁疗程治愈的十二指肠溃疡患者被随机分配至每日两次服用400毫克西咪替丁或安慰剂组。对每组复发次数的精算分析表明,西咪替丁在预防复发方面非常有效。